{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:52:29Z","timestamp":1771041149834,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1136\/ijgc-2020-001529","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T02:45:12Z","timestamp":1594608312000},"page":"1418-1423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Urinary symptoms in women receiving carboplatin\/paclitaxel for treatment of gynecologic cancers"],"prefix":"10.1016","volume":"30","author":[{"given":"Christopher J","family":"Strauchon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-5868","authenticated-orcid":false,"given":"Payam","family":"Katebi Kashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattew J","family":"Aungst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Trikhacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Bicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walter","family":"Von Pechmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001529_bb0010","author":"Noone","year":"2018"},{"key":"10.1136\/ijgc-2020-001529_bb0015","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/00016340801948326","article-title":"Long-term consequences of gynecological cancer treatment on urinary incontinence: a population-based cross-sectional study","volume":"87","author":"Skjeldestad","year":"2008","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1136\/ijgc-2020-001529_bb0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00192-008-0755-z","article-title":"Urinary symptoms and impact on quality of life in women after treatment for endometrial cancer","volume":"20","author":"Erekson","year":"2009","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1136\/ijgc-2020-001529_bb0025","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/GRF.0b013e31824b45da","article-title":"First-line chemotherapy in epithelial ovarian cancer","volume":"55","author":"Bookman","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-001529_bb0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1212\/WNL.47.1.115","article-title":"Motor neuropathy due to docetaxel and paclitaxel","volume":"47","author":"Freilich","year":"1996","journal-title":"Neurology"},{"key":"10.1136\/ijgc-2020-001529_bb0035","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001529_bb0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2008.01.008","article-title":"Peripheral nerve damage associated with administration of taxanes in patients with cancer","volume":"66","author":"Argyriou","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1136\/ijgc-2020-001529_bb0045","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0b013e32830b58b0","article-title":"Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report","volume":"19","author":"Stemmler","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.1136\/ijgc-2020-001529_bb0050","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1136\/ijgc-2020-001529_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5213\/inj.1836084.042","article-title":"Factors influencing lower urinary tract symptoms in advanced cancer patients with chemotherapy-induced peripheral neuropathy","volume":"22","author":"Cho","year":"2018","journal-title":"Int Neurourol J"},{"key":"10.1136\/ijgc-2020-001529_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/nau.1930140206","article-title":"Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Continence Program for Women Research Group","volume":"14","author":"Uebersax","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"10.1136\/ijgc-2020-001529_bb0065","doi-asserted-by":"crossref","first-page":"M67","DOI":"10.1093\/geronj\/45.2.M67","article-title":"Two-year incidence, remission, and change patterns of urinary incontinence in noninstitutionalized older adults","volume":"45","author":"Herzog","year":"1990","journal-title":"J Gerontol"},{"key":"10.1136\/ijgc-2020-001529_bb0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s00192-005-0060-z","article-title":"Validity of the incontinence severity index: comparison with pad-weighing tests","volume":"17","author":"Sandvik","year":"2006","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1136\/ijgc-2020-001529_bb0075","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1525-1438.2007.00794.x","article-title":"Validation and reduction of FACT\/GOG-Ntx subscale for platinum\/paclitaxel-induced neurologic symptoms: a Gynecologic Oncology Group study","volume":"17","author":"Huang","year":"2007","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001529_bb0080","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ajog.2009.02.007","article-title":"The minimum important differences for the urinary scales of the pelvic floor distress inventory and pelvic floor impact questionnaire","volume":"200","author":"Barber","year":"2009","journal-title":"Am J Obstet Gynecol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24006686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24006686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:25:44Z","timestamp":1753233944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24006686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1048891X24006686"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001529","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary symptoms in women receiving carboplatin\/paclitaxel for treatment of gynecologic cancers","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001529","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}